A Rabies-Specific Human Monoclonal Antibody That Protects Mice Against Lethal Rabies
| Autor: | F. R. Seiler, K Enssle, R. Köhler, E. J. Kanzy, H. Müller, R. Kurrle, J. Hilfenhaus |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Serotype
Rabies medicine.drug_class Immunology Antibodies Viral medicine.disease_cause Monoclonal antibody Virus Mice Viral Envelope Proteins Antibody Specificity Genetics medicine Animals Humans Antigens Viral Lyssavirus Cell Line Transformed Glycoproteins biology Rabies virus Immunization Passive Antibodies Monoclonal Rhabdoviridae biology.organism_classification medicine.disease Virology Leukocytes Mononuclear biology.protein Antibody |
| Zdroj: | Hybridoma. 10:547-556 |
| ISSN: | 0272-457X |
| DOI: | 10.1089/hyb.1991.10.547 |
| Popis: | According to a recommendation from WHO (World Health Organisation) for prevention of a possible rabies infection, active vaccination has to be combined with application of immunoglobulin to get a fast protective effect. At present, preparations of purified human or equine rabies-specific immunoglobulin are used. We have generated a human rabies-specific monoclonal antibody (huMAb) by immortalization of human B-cells with Epstein Barr Virus (EBV), followed by fusion with a mouse myeloma cell. The resulting clone TW-1 secrets an IgG1 lambda huMAb which specifically reacts in ELISA with 5 laboratory rabies virus strains of serotype 1 and DUV3 (Duvenhage, serotype 4). Western Blot analysis revealed fine specificity for the G glycoprotein (gp67) of rabies virus. HuMAb TW-1 neutralizes rabies virus in vitro (RFFIT) as well as in vivo and protects rabies infected mice. Compared to polyclonal human rabies immunoglobulins, huMAb TW-1 is advantageous, because of its defined specificity and the very low amounts of total protein needed for therapeutic effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|